Associations of Physician Perspectives, Personal Choices, and Counseling for Severe Congenital Heart Defects

Joyce L Woo1, Tara M Swanson2, Shiraz A Maskatia3

  • 1Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Prenatal Diagnosis
|September 23, 2025
PubMed

Insights

Physician counseling for termination of pregnancy or perinatal hospice for congenital heart defects (CHDs) is linked to their personal choices, not just outcome views. Understanding these personal beliefs is key for informed family decisions.

Area of Science:

  • Cardiology
  • Medical Ethics
  • Neonatal Care

Background:

  • Congenital heart defects (CHDs) present complex decisions for families regarding pregnancy termination or perinatal hospice.
  • Physician perspectives on outcomes and personal beliefs may influence prenatal counseling for these challenging situations.

Purpose of the Study:

  • To determine if physician views on congenital heart defect (CHD) outcomes or personal choices influence their counseling on termination of pregnancy (TOP) or perinatal hospice.
  • Investigating the association between physician perspectives and prenatal counseling practices for severe CHDs.

Main Methods:

  • A multicenter survey was conducted among US pediatric cardiologists and congenital heart surgeons from 2016-2018.
  • The survey assessed physician perspectives on CHD outcomes, personal considerations, and counseling for TOP or perinatal hospice.
  • Bivariate analyses were used to examine associations between outcome perspectives, personal choices, and counseling.

Main Results:

  • While 47% believed single-ventricle defects offer good long-term quality of life, most physicians (70%-90%) would consider perinatal hospice for their own child, but few (2%-16%) would choose it over intervention.
  • Physicians considering TOP for themselves were significantly more likely to counsel about TOP (99% vs. 67%).
  • No association was found between institutional practice, outcome perspectives, or personal hospice considerations and counseling practices.

Conclusions:

  • Physician perspectives on single-ventricle outcomes, though guarded, did not correlate with counseling practices.
  • Personal choices and considerations significantly influence counseling regarding termination of pregnancy or perinatal hospice for CHDs.
  • Incorporating physicians' personal beliefs is essential for providing comprehensive counseling to families facing decisions about severe CHDs.
Abstract

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
339
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
414
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
261
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
215
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
220
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
480